Market Logic launches DeepSights Agents to transform scale and speed of innovation processes
Agentic AI for Insights marks a revolutionary leap forward, systematically driving innovative product development across industries
BERLIN, June 17, 2025 /CNW/ -- Market Logic, the market leading provider of insights management solutions, today announced another breakthrough for AI-driven market intelligence with the introduction of DeepSights Agents. The first agents to be released are specifically trained to identify white space opportunities, develop and refine ideas and build out robust new product concepts. By employing DeepSights Agents, companies will be able to reduce innovation cycle times by more than half.
Two types of DeepSights Agents will underpin a new model for driving business impact from AI-based market intelligence technology. Together they will provide end to end support for new product-development.
Always-on DeepSights Consumer Trends Agents provide enterprises with round the clock monitoring and analysis of market data. This marks a significant shift in how insights are collected and shared, moving from time intensive manual processes to proactive, fully automated processes.
On-demand, goal-centric DeepSights Innovation Agents will join forces with human teams and work iteratively in a human/AI collaborative framework to deliver complex projects in a fraction of the time. These specialist AI Agent teams will be embedded within a ready to use application called DeepSights Innovation Studio. As well as on-demand Agents, the application contains customisable workflows and templates which steer users through the innovation process.
"It's time to move market research and intelligence into the driving seat for growth strategies. Agentic AI presents an opportunity to make sense of market signals 24 x 7 and accelerate innovation momentum. Companies that redefine their processes to embrace these capabilities will be the ones to anticipate consumer needs and steal a march on their competition," said Olaf Lenzmann, Chief product and innovation officer, Market Logic Software.
"When the pace of innovation slows, growth inevitably slows. We see the potential for DeepSights Agents to reverse this decline and enable a step-change in the volume of high-quality concepts brands bring into their innovation pipeline. Our proven ideation methodology will benefit by applying this systematic, data-driven approach to innovation process for our customers," said Richard Davies, founder, Alchemy-RX.
Across industries, companies are under pressure to introduce new products to stay ahead of the competition. In Consumer-Packaged Goods (CPG), market leaders expect 10% to 20% of revenues to come from new products, in Pharmaceuticals this ratio is even higher, rising to 30%. However, many brands have fallen behind on achieving these targets because costly and difficult manual processes cannot keep up with the demands of a robust innovation pipeline.
DeepSights Agents, will be in general release from August, and can be deployed across multiple industries including Pharmaceuticals, CPG, Retail, and Financial Services. Expert services support from Market Logic and its partner network will ensure optimal set up and integration of DeepSights Agents to meet the unique requirements of your market focus. Contact our experts to explore capabilities in detail: https://marketlogicsoftware.com/deepsights-agents/.
Market Logic is the leading SaaS provider of market intelligence and insights solutions. Our AI market insights platform, powered by our special purpose AI for Insights technology DeepSights, allows insights teams to equip business decisions makers with trusted insights at scale and speed. For more than 15 years, we've helped hundreds of consumer-focused brands across the globe to transform into insights-driven businesses. Market leaders such as Unilever, Vodafone, Bayer, and Tesco are driving innovation and making smarter market moves with the support of Market Logic.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Dahon Founder Showcased New Lineup, Revolutionary Patented Bike Tech at Eurobike 2025
FRANKFURT, Germany, June 28, 2025 /CNW/ -- Led by Dr. David Hon, Founder & CEO, DAHON unveiled a lineup of innovative new products at EUROBIKE 2025, drawing widespread attention with its DAHON 2.0 Campaign backed by its proprietary DAHON-V bike tech promising improved performance across all lines of products. The impressive product lineup attracted major industry figures such as executives from Giant and Golden Wheel Group, along with many of DAHON's European distribution partners. Major cycling media such as Global Cycling Network (GCN) Tech also grace the occasion to report on the product showcase. New Product Highlights K-Feather – Ultralight E-Bike With an ultra-compact design weighing just 12 kg, the K-Feather integrates a high-density hidden battery and torque sensor for up to 40 km of intelligent power output. Its minimalist design makes it a top choice for urban commuters, and a true fusion of technology and aesthetics. Télodon C8 AXS – Carbon Frame Folding Bike DAHON's first single-beam carbon fiber folding road bike features an exclusive internal V-fold mechanism that keeps its folded form as sleek and simple. Combined with patented DELTECH and Super Downtube, it offers enhanced frame stiffness and extended lifetime. Equipped with a SRAM AXS wireless shifting system and UDH, it ensures precise, stable performance at high speeds. Vélodon C8 Di2 – Carbon Frame Roadbike Designed with DAHON-V tech, featuring an aerodynamic frame design and Shimano Ultegra Di2 electronic shifting. Frame stiffness is increased by 20–30% compared to standard carbon road bikes, offering a powerful yet agile ride. DAHON Electric Lineup DAHON's electric lineup marks a new era in powered cycling. With five series ranging in size and use case, ranging from electric-assist bikes to mopeds, e-motorcycles and e-trikes. These smart, user-friendly features reflect DAHON's mission to make everyday mobility easier, smarter, and more enjoyable. Visit DAHON at Booth A12, Hall 12 during June 25 – 29, 2025.
Cision Canada
11 hours ago
- Cision Canada
Freegold Ventures Limited - Results of the Annual General and Special Meeting
VANCOUVER, BC, June 27, 2025 /CNW/ - Freegold Ventures Limited (TSX: FVL) (OTCQX: FGOVF) ("Freegold" or the "Company") is pleased to announce that all matters set out in the Management Information Circular dated May 26, 2025 for the 2025 Annual General and Special Meeting of Shareholders held on June 27, 2025 (the "Meeting") were approved by the shareholders holding 98,154,137 shares were voted representing approximately ~ 18.56% of the outstanding shares of the Company. The following nine nominees were elected as directors of Freegold. The detailed results of the vote for the election of directors are set out below: The Company's shareholders approved the appointment of Davidson & Company LLP, Chartered Professional Accountants, as the Company's auditors, as set forth in the management information circular. The Company's shareholders approved the Company's new omnibus equity incentive plan. Each of the matters voted upon at the Meeting is discussed in detail in the Company's Information Circular dated May 26 th, 2025, which is filed under the Company's profile at Golden Summit Project Update: Drilling at Golden Summit is progressing well. Drilling is focused on resource definition, which includes both expansion and infill drilling, as well as geotechnical and metallurgical holes. Like the 2024 drill program, the current efforts aim to upgrade inferred resources to indicated status in preparation for the upcoming pre-feasibility study, which is expected to commence later this year. An updated mineral resource estimate is expected to be finalised soon, and the initial assay results from the 2025 drill program are also anticipated shortly. The Qualified Person for this release is Alvin Jackson, Vice President of Exploration and Development for Freegold, who has approved the scientific and technical disclosure in this news release. About Freegold Ventures Limited Freegold is a TSX-listed company focused on exploration in Alaska. It holds the Golden Summit Gold Project near Fairbanks and the Shorty Creek Copper-Gold Project near Livengood through leases. Some statements in this news release contain forward-looking information, including, without limitation, statements as to planned expenditures and exploration programs, potential mineralization and resources, exploration results, the completion of an updated NI 43-101 technical report, and any other future plans. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the statements. Such factors include, without limitation, the completion of planned expenditures, the ability to complete exploration programs on schedule, and the success of exploration programs. See Freegold's Annual Information Form for the year ended December 31st, 2024, filed under Freegold's profile at for a detailed discussion of the risk factors associated with Freegold's operations. On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a global health emergency. Reactions to the spread of COVID-19 continue to lead to, among other things, significant restrictions on travel, business closures, quarantines, and a general reduction in economic activity. While these effects have been reduced in recent months, the continuation and re-introduction of significant restrictions, business disruptions, and related financial impact, and the duration of any such disruptions cannot be reasonably estimated. The risks to Freegold of such public health crises also include employee health and safety risks and a slowdown or temporary suspension of operations in geographic locations impacted by an outbreak. Such public health crises, as well as global geopolitical crises, can result in volatility and disruptions in the supply and demand for various products and services, global supply chains, and financial markets, as well as declining trade and market sentiment and reduced mobility of people, all of which could affect interest rates, credit ratings, credit risk, and inflation. As a result of the COVID-19 outbreak, Freegold has implemented a COVID management program and established a full-service Camp at Golden Summit to attempt to mitigate risks to its employees, contractors, and community. While the extent to which COVID-19 may impact Freegold is uncertain, it is possible that COVID-19 may have a material adverse effect on Freegold's business, results of operations, and financial condition.
Cision Canada
12 hours ago
- Cision Canada
LSL PHARMA GROUP ANNOUNCES VOTING RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
BOUCHERVILLE, QC, June 27, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (" LSL Pharma" or the " Corporation"), a Canadian integrated pharmaceutical company, today announced the voting results of its annual general and special meeting of shareholders held today in Boucherville, Québec at the Corporation's headquarters (the " Meeting"). Election of Directors Mr. François Roberge, Mr. Frank Dellafera, Mr. Mario Paradis and Mr. Louis Laflamme were elected directors of the Corporation to hold office until the next annual meeting of shareholders or until their successors are appointed or elected. Each of the remaining director nominees have received less than 50% of the votes cast in favour of their election. At the Corporation's request, these nominees may continue in office, for a maximum of 90 days for transition purposes, after which the Board will accept their resignations. Full voting results are available on SEDAR+ at Appointment of Auditors Audacie Inc. has been re-appointed as auditors of the Corporation for the ensuing year and the directors are authorized to fix their remuneration. Approval of Stock Option Plan The current 10% rolling stock option plan of the Corporation has been re-approved until the next annual meeting of shareholders. Further disclosure on the matters approved at the Meeting, including full voting results, can be found in the notice and accompanying management information circular filed in respect of the Meeting and available on SEDAR+ at ABOUT LSL PHARMA GROUP INC. LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceutical products, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. Companies forming part of LSL Pharma Group include Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Santé Inc. and Dermolab Pharma Ltée. For further information, please visit our website at CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release may contain forward-looking statements as defined under applicable Canadian securities legislation. Forward-looking statements can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "continue" or similar expressions. Forward-looking statements are based on a number of assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Corporation's ability to control or predict, that could cause actual results or performance to differ materially from those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, those identified in the Corporation's filings with Canadian securities regulatory authorities, such as legislative or regulatory developments, increased competition, technological change and general economic conditions. All forward-looking statements made herein should be read in conjunction with such documents. Readers are cautioned not to place undue reliance on forward-looking statements. No assurance can be given that any of the events referred to in the forward-looking statements will transpire, and if any of them do, the actual results, performance or achievements of the Corporation may differ materially from those expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. The Corporation does not undertake to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) have reviewed or accept responsibility for the adequacy or accuracy of this release. SOURCE Groupe LSL PHARMA INC.
